Intrinsic Resistance to Chemotherapy in Breast Cancer-Reference-Cited by-同舟云学术

Intrinsic Resistance to Chemotherapy in Breast Cancer

Published:2010-11 Issue:6 Volume:6 Page:821-830
ISSN:1745-5065
Container-title:Women's Health
language:en
Short-container-title:Womens Health (Lond Engl)

Author:

Moulder Stacy¹

Affiliation:

1. Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, PO Box 301438, Houston, TX 77030, USA, Tel.: +1 713 792 2817, Fax: +1 713 794 4385,

Abstract

Systemic therapy improves disease-free survival in patients with breast cancer, but does not cure patients with advanced or metastatic disease, and fails to benefit the majority of patients with localized breast cancer. Intrinsic resistance to chemotherapy is emerging as a significant cause of treatment failure and evolving research has identified several potential causes of resistance, such as drug efflux pumps, disregulation of apoptosis and cancer stem cells. Building upon preclinical models, drugs designed to reverse resistance to therapy are currently under investigation in clinical trials for the treatment of breast cancer.

Publisher

SAGE Publications

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.2217/WHE.10.60

Reference88 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2. Drug resistance and cancer chemotherapy strategy in breast cancer

3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

4. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

5. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance;Advances in Cancer Research;2023

2. UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress;NAR Cancer;2022-09-28

3. Hypoxia-regulated microRNAs: the molecular drivers of tumor progression;Critical Reviews in Biochemistry and Molecular Biology;2022-07-04

4. Single-cell RNA sequencing and bioinformatics as tools to decipher cancer heterogenicity and mechanisms of drug resistance;Biochemical Pharmacology;2022-01

5. Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer;Drug Resistance Updates;2022-01